RESEARCH IN PULMONARY HYPERTENSION

"PHA's research program has yielded an explosion of understanding about PH that was not known before."
- John Newman, MD, Vanderbilt University Medical Center

Twenty years ago there were no pulmonary hypertension treatments available. Through focused research there are now eight PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.

PHA’s Research Program

In just a little under a decade, PHA’s Research Program has committed almost $9 million for PH research by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI), American Thoracic Society (ATS) and the American Heart Association (AHA). We have supported over 44 promising researchers through three independently reviewed cutting-edge research programs.

Read more about PHA’s Research Program

Learn more

Current Treatments

PHA’s Scientific Leadership Council’s Education Committee has put together comprehensive factsheets on all the treatments available for pulmonary hypertension. Read more about current treatments

Research Corner in Pathlight

Every issue of PHA’s quarterly print newsletter Pathlight features a Research Corner with information about some of the latest research. Read more


Pulmonary Hypertension Research News
Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension
(PRNewswire) - Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy.  VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease.  Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010. Read article
Wednesday, August 25, 2010 3:36:46 PM
Potential Treatment For Pulmonary Hypertension
(Medical News Today) - Researchers in the Faculty of Medicine & Dentistry at the University of Alberta are one step closer to a treatment for PAH. Read article

Friday, August 13, 2010 6:08:48 PM
Pfizer's Viagra Weighed by U.S. FDA for Children With PAH
7/27/10 (Bloomberg) - Revatio may be used for children with a rare lung disorder if U.S. regulators can agree on how to test it. Outside advisers to the Food and Drug Administration are set to meet July 29 to evaluate whether Pfizer’s study of Revatio is sufficient to determine its effectiveness in children, the agency said today. Read article
Wednesday, July 28, 2010 11:48:49 AM
Data Published on Novartis QT1571 for Treatment of Severe Pulmonary Arterial Hypertension
7/9/10 (pharmiweb.com) - The proof of concept study to assess the safety, tolerability and efficacy of QTI571 (imatinib) in patients with pulmonary arterial hypertension (PAH) was published in the American Journal of Respiratory and Critical Care Medicine. QTI571, a tyrosine kinase inhibitor, was studied in patients with PAH not adequately controlled with currently licensed medications. QTI571 significantly improved exercise capacity and pulmonary haemodynamics compared with placebo in patients with severe PAH. Read press release
Tuesday, July 13, 2010 1:32:11 PM
Researchers Point to Possible Scleroderma-Cancer Link

7/9/10 (HealthDay News) - People with specific antibodies may develop both cancer and a certain type of scleroderma -- an incurable autoimmune disease -- at nearly the same time, new research finds. The finding, from a small study of 23 patients, hints at a possible link between cancer and autoimmune disorders. Read article


Monday, July 12, 2010 10:38:00 AM


Patients & Families

Woman having blood drawn

Participating in research & clinical trials helps provide information vital to progress toward a cure.

Learn more about participating in research

MEDICAL PROFESSIONALS

beakers in a lab

Research grant opportunities are available from PHA’s Research Program in the field of PH.

Learn more and apply today


Donate to Research

ADVOCATE FOR RESEARCH FUNDING

Put your Members of Congress to work for you, their constituent. Ask them to support federal funding for PH research and education.

Advocate for PH research funding

Email Updates

Stay informed about current research, events, and more.

Sign up

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

For the best viewing experience of this site, it is recommended that you use Internet Explorer 7 or 8 or Firefox.

© 2010 Pulmonary Hypertension Association. All Rights Reserved.

We've moved! We are in Ste. 1000 of the same building.
801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Helpline: 1-800-748-7274
PHA@PHAssociation.org    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Created by Matrix Group International, Inc.®